PTHS
Pelthos Therapeutics Inc.
NYSE MKT: PTHS · HEALTHCARE · BIOTECHNOLOGY
$25.09
+0.48% today
Updated 2026-04-29
Market cap
$83.79M
P/E ratio
—
P/S ratio
4.99x
EPS (TTM)
$-23.04
Dividend yield
—
52W range
$9 – $38
Volume
0.0M
Pelthos Therapeutics Inc. (PTHS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $199934.00 | $0.00 | $0.00 | $0.00 | $0.00 | $16.80M |
| Revenue growth (YoY) | — | -100.0% | — | — | — | — |
| Cost of revenue | — | — | — | — | $0.00 | $6.27M |
| Gross profit | $199934.00 | — | — | — | $0.00 | $10.52M |
| Gross margin | 100.0% | — | — | — | — | 62.6% |
| R&D | $138585.00 | $209047.00 | $391730.00 | $2.58M | $1.18M | $1.23M |
| SG&A | — | $629949.00 | $1.93M | $4.28M | $6.39M | $37.08M |
| Operating income | $-1.35M | $-838996.00 | $-2.32M | $-6.86M | $-7.57M | $-32.43M |
| Operating margin | -677.2% | — | — | — | — | -193.1% |
| EBITDA | $-658908.00 | $-595134.00 | $-2.32M | $-6.86M | $-7.17M | $-30.07M |
| EBITDA margin | -329.6% | — | — | — | — | -179.0% |
| EBIT | — | — | — | — | — | $-32.43M |
| Interest expense | $1676.00 | $253.00 | $140430.00 | $518509.00 | $786393.00 | $3.01M |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-660584.00 | $-595387.00 | $-2.46M | $-7.38M | $-7.96M | $-43.32M |
| Net income growth (YoY) | — | +9.9% | -312.9% | -200.2% | -7.8% | -444.5% |
| Profit margin | -330.4% | — | — | — | — | -257.9% |